Status:
COMPLETED
Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will estimate overall response rate of pemetrexed in poor risk patients with advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.
Detailed Description
Rationale: Patients with advanced stage head and neck cancer, especially those with disease in the hypopharynx, oropharynx, or oral cavity, and poor performance status defined through clinical testing...
Eligibility Criteria
Inclusion
- Advanced, metastatic, or recurrent head and neck cancers
- Poor risk patients with ECOG performance status of 2
Exclusion
- Prior treatment for recurrent or metastatic disease
- No clinical or radiological evidence of brain metatases
- Patients with bone only disease are not eligible
- Patients with pleural or peritoneal effusion as only manifestation of diesase
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00293579
Start Date
February 1 2006
End Date
November 1 2008
Last Update
February 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University
Columbus, Ohio, United States, 43210